Sonoma Biotherapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sonoma Biotherapeutics, Inc. - overview
Established
2020
Location
South San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2020, Sonoma Biotherapeutics, Inc. develops adoptive Treg therapies cell for autoimmune and inflammatory diseases. The company was co-founded by Alexander Rudensky, Fred Ramsdell, Jeffrey Bluestone (CEO), and Qizhi Tang. As of August 2021, the company raised a total funding of USD 335 million from investors including Mirae Asset Venture Investment, Ally Bridge Group, Casdin Capital, and Deep Track Capital.
The company's programs include SBT-77-7101, a novel CAR-based Treg cell therapy for patients with refractory rheumatoid arthritis, SBT-11-5301, a Teff conditioning biologic designed to help clear the inflammatory environment and make Treg cell therapies effective, and SBT-77-7200 Series for other autoimmune and inflammatory diseases. The company plans to advance its Bio’s Treg cell therapy platform and a novel Teff conditioning biologic into the clinic to treat multiple, severe autoimmune, and inflammatory diseases, and to further invest in and further enhance its manufacturing operations in order to support supply for initial clinical studies.
Current Investors
ARCH Venture Partners, 8VC, Milky Way Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.sonomabio.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.